Ocular Therapeutix, Inc. (NASDAQ:OCUL) Stock Has Consensus Price Target of $23.33

Ocular Therapeutix, Inc. (NASDAQ:OCUL) has earned an average recommendation of “Moderate Buy” from the eleven brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $23.33.

A number of analysts have recently weighed in on OCUL shares. Chardan Capital restated a “buy” rating and issued a $23.00 target price on shares of Ocular Therapeutix in a research note on Friday, October 2nd. Royal Bank Of Canada reissued an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday, September 29th. Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, October 15th. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 price target on shares of Ocular Therapeutix in a research note on Monday, October 19th.

Insider Activity at Ocular Therapeutix

In other news, insider Todd Anderman sold 11,984 shares of the firm’s stock in a transaction dated Thursday, October 8th. The shares were sold at an average price of $7.29, for a total value of $87,363.36. Following the transaction, the insider owned 140,484 shares of the company’s stock, valued at approximately $1,024,128.36. This trade represents a 7.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Namrata Saroj sold 35,370 shares of the business’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $6.55, for a total transaction of $231,673.50. Following the sale, the insider directly owned 220,522 shares of the company’s stock, valued at approximately $1,444,419.10. This trade represents a 13.82% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 98,090 shares of company stock valued at $787,920 over the last quarter. 3.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC increased its holdings in shares of Ocular Therapeutix by 8.1% during the third quarter. Commonwealth Equity Services LLC now owns 20,992 shares of the biopharmaceutical company’s stock worth $161,000 after buying an additional 1,575 shares in the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Ocular Therapeutix during the 4th quarter valued at $31,000. Principal Financial Group Inc. boosted its holdings in shares of Ocular Therapeutix by 24.1% during the 1st quarter. Principal Financial Group Inc. now owns 13,623 shares of the biopharmaceutical company’s stock valued at $115,000 after acquiring an additional 2,642 shares in the last quarter. NewEdge Advisors LLC grew its position in Ocular Therapeutix by 21.7% during the 2nd quarter. NewEdge Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock worth $164,000 after acquiring an additional 2,979 shares during the last quarter. Finally, Raiffeisen Bank International AG grew its position in Ocular Therapeutix by 5.3% during the 2nd quarter. Raiffeisen Bank International AG now owns 100,000 shares of the biopharmaceutical company’s stock worth $990,000 after acquiring an additional 5,000 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix News Roundup

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Ocular Therapeutix said it plans to submit an AXPAXLI NDA in the fourth quarter of 2026. The company reported $530.6 million in cash, which it expects to fund operations into 2028, helping ease near-term financing concerns. Article: AXPAXLI NDA plan and cash runway
• Neutral Sentiment: The company appointed Riad Sherif to its board of directors, a governance update without an immediately clear financial impact. Article: Board appointment
• Neutral Sentiment: Insider Namrata Saroj sold 35,370 shares under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards. The stated reason and existing plan make the sale less indicative of a discretionary view on the stock. SEC insider transaction filing
• Negative Sentiment: Third-quarter adjusted loss was $0.42 per share, worse than the $0.36 loss analysts expected; revenue of $12.87 million also missed the $14.27 million consensus and fell 11.5% year over year. The earnings shortfall and weaker sales contributed to pressure on OCUL shares. Article: Ocular Therapeutix falls on third-quarter earnings miss
• Negative Sentiment: Coverage also highlighted costs associated with advancing AXPAXLI and declining DEXTENZA sales, raising questions about near-term operating performance as the company pursues its pipeline. Article: Q3 results, pipeline costs, and DEXTENZA

Ocular Therapeutix Price Performance

Ocular Therapeutix stock opened at $6.85 on Thursday. The stock has a fifty day moving average price of $8.33 and a two-hundred day moving average price of $9.00. Ocular Therapeutix has a 52-week low of $6.00 and a 52-week high of $16.44. The company has a current ratio of 13.10, a quick ratio of 13.03 and a debt-to-equity ratio of 0.14.

Ocular Therapeutix (NASDAQ:OCUL) last announced its quarterly earnings results on Monday, November 9th. The biopharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.06). The firm had revenue of $12.87 million for the quarter, compared to the consensus estimate of $14.27 million. Ocular Therapeutix had a negative net margin of 579.10% and a negative return on equity of 59.89%. The company’s revenue for the quarter was down 11.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.38) earnings per share. On average, equities research analysts anticipate that Ocular Therapeutix will post -1.47 earnings per share for the current year.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company focused on developing and commercializing treatments for eye diseases and conditions. Based in Bedford, Massachusetts, the company uses its proprietary hydrogel-based technology to deliver medicines to the eye over time.

Its marketed product, DEXTENZA, is a corticosteroid insert placed in the tear duct by an eye-care professional to treat inflammation and pain following ophthalmic surgery. Ocular Therapeutix also develops investigational therapies for retinal diseases and other eye conditions, including treatments designed for sustained drug delivery.

The company was founded in 2006 and serves the U.S.